Iconix Biosciences has developed leading products and services that apply novel and proprietary genomic technologies to profile candidate drug compounds in early discovery through to pre-clinical development, leading to a better understanding of candidate drugs in a faster, more cost-effective manner. The toxicology community is embracing this approach to increase the accuracy, sensitivity and speed of toxicity testing. The company has identified the factors and is creating the environment that will lead to a "tipping point" in the pharmaceutical and biotech industries such that toxicogenomics becomes a standard practice in the drug discovery and development process. Changing this paradigm will significantly impact the failure rate of late stage preclinical compounds and provide a compelling return on investment.

Iconix is improving drug safety and efficacy through application of genomics technology to predict therapeutic success. We enable pharmaceutical and biotech customers to progress the right compounds more efficiently through drug discovery and development and apply critical tools that aid in the selection of the right treatments for patients. The company has developed leading edge technology, intellectual property and unparalleled internal expertise in toxicogenomics - the science of applying gene expression profiling to the understanding of mechanisms of toxicity, and pharmacologic and toxicological biomarker identification and validation for preclinical drug discovery and development. We offer these capabilities and technologies to pharmaceutical and biotechnology partners as well as the US FDA, through multiple levels of service and collaborations that meet customer needs and extend their drug discovery and development resources.

Iconix Biosciences, Inc. is now part of Entelos, Inc. where the Iconix team continues to deliver the best toxicogenomics solutions. Please see the Entelos website for information about additional products and services.